 I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI New majority independent ESG committee to set overall ESG strategies for the Company Women account for two-thirds of the total workforce and over 30 of I-Mabs Board of Directors Committed to diversity, equity and inclusion, I-Mab has launched Womens Leadership Council in 2020 and has been awarded T Excellent Employer for its accomplishments in diversity and innovation SHANGHAI and GAITHERSBURG, MD., Aug. 19, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors the Board approved establishment of an ESG Environmental, Social and Governance Committee. 